Text Size

Hemodynamics During the Soccer Championship 2012

This study has been completed.
Sponsor:
Collaborators:
Universitätsklinikum Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
Universitätsklinikum Erlangen, Erlangen, Bayern, Germany
Universitätsklinikum Eppendedorf, Hamburg, Germany
UKSH Campus Kiel, Kiel, Germany
Information provided by (Responsible Party):
PD. Dr. med Michael Reppel, University of Schleswig-Holstein
ClinicalTrials.gov Identifier:
NCT01617863
First received: June 8, 2012
Last updated: July 2, 2012
Last verified: June 2012
History of Changes
  Purpose

The purpose of this study is to determine in soccer fans whether and to which extend positive or negative emotions during the European soccer Championship affects Central Hemodynamics, Arterial Stiffness, Heartrate and Endothelial Dysfunktion.


Condition
Severe Cardiomyopathy
Angina, Unstable
Myocardial Infarction
Angina, Stable

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Central Hemodynamics, Arterial Stiffness, Heartrate and Endothelial Dysfunktion During the European Soccer Championship 2012

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Schleswig-Holstein:

Biospecimen Retention:   Samples Without DNA

EDTA-Blood, Serum


Estimated Enrollment: 180
Study Start Date: June 2012
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

primary care clinic, clinical employees, students

Criteria

Inclusion Criteria:

Best fit:

  • cardiomyopathy "severe myocardial disease leading to heart failure"
  • Angina, stable for at least 7 days
  • Myocardial infarction during 4 weeks before inclusion, actually stable condition
  • Angina, Stable, CCS II-IV

Exclusion Criteria:

  • not interested in soccer championship
  • age <18y
  • dementia
  • atrial tachycardia
  • drug/alcohol abuse
  • chronic kidney disease, stage 5
  • pulmonary/tricuspid valve insufficiency/stenoses
  • non compliant
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01617863

Locations
Germany
Universitätsklinikum Erlangen
Erlangen, Bayern, Germany, 91054
Universitätsklinikum Greifswald
Greifswald, Mecklenburg-Vorpommern, Germany, 17475
UKSH-Lübeck
Lübeck, Schleswig-Holstein, Germany, 23538
Universitätsklinikum Eppendorf
Hamburg, Germany
Sponsors and Collaborators
University of Schleswig-Holstein
Universitätsklinikum Greifswald, Greifswald, Mecklenburg-Vorpommern, Germany
Universitätsklinikum Erlangen, Erlangen, Bayern, Germany
Universitätsklinikum Eppendedorf, Hamburg, Germany
UKSH Campus Kiel, Kiel, Germany
Investigators
Study Director: Michael Reppel, PD. Dr. med UKSH- Lübeck Medizinische Klinik 2
  More Information

No publications provided

Responsible Party: PD. Dr. med Michael Reppel, PD Dr. med Reppel, University of Schleswig-Holstein
ClinicalTrials.gov Identifier: NCT01617863     History of Changes
Other Study ID Numbers: HL-Med2-EM-2012
Study First Received: June 8, 2012
Last Updated: July 2, 2012
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Angina Pectoris
Angina, Unstable
Infarction
Myocardial Infarction
Cardiomyopathies
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
 Vascular Diseases
Chest Pain
Pain
Signs and Symptoms
Ischemia
Pathologic Processes
Necrosis

ClinicalTrials.gov processed this record on May 22, 2013